Will defenders of Merck’s and Schering-Plough’s beleaguered cholesterol drug Zetia find solace in a clinical trial called Sands?
It’s possible because results appearing in the current issue of JAMA suggest that Zetia, also an ingredients in Vytorin, might have helped patients at high risk of heart disease by the same measure in which it failed in [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment